Inside the research
Bio-Rad Laboratories, Inc.
BIO Research profile · latest available data
Price overview
$381.00
▼ -6.54 (-1.7%)
| 52w hi | $390.34 |
|---|---|
| 52w lo | $241.71 |
| Vol | 253.60K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.47
| Short | +0.53 |
|---|---|
| Medium | +0.57 |
| Long | +0.12 |
computed 2026-09-27
Key fundamentals
Bio-Rad Laboratories, Inc.
Healthcare · Medical Devices
| Market cap | $10.19B |
|---|---|
| Enterprise value | $9.94B |
| Trailing P/E | 46.52x |
| Forward P/E | 37.69x |
| EV / EBITDA | 22.54x |
| P / S (ttm) | 3.94x |
| Profit margin | 8.6% |
| Return on equity | 3.1% |
| Revenue growth | -0.1% |
| Earnings growth | +18.7% |
| Debt / equity | 19.10 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.12 | |
| Sector | +0.08 | |
| Technical | +0.40 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Risk Metrics
| Beta vs SPX | 0.92 |
|---|---|
| Corr SPX | 0.36 |
| Annual vol | 40.7% |
| Annual ret | +15.4% |
| Sharpe | 0.38 |
| Max DD | -42.1% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Restructuring… | read |
| 2026-04-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-04-24 | Officer / Director Change, Shareholder Vote… | read |
| 2026-02-19 | Reg FD Disclosure | read |
| 2026-02-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-29 | Earnings Release, Reg FD Disclosure… | read |
| 2025-09-30 | Reg FD Disclosure, Exhibits | read |
| 2025-08-26 | Reg FD Disclosure, Exhibits | read |
| 2025-07-31 | Earnings Release, Reg FD Disclosure… | read |
| 2025-07-28 | Officer / Director Change, Other Material Event… | read |
| 2025-06-30 | Other Material Event | read |
| 2025-05-01 | Earnings Release, Exhibits | read |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.58B | +2.0% | |
| Gross profit | $1.43B | +2.7% | |
| Operating income | $47.20M | -11.3% | |
| Net income | -$1.84B | +19.5% | |
| Cash from ops | $532.20M | +7.1% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $384.14 | $387.00 | $376.43 | $381.00 | 253.60K |
| Sep 24 | $377.73 | $389.38 | $376.18 | $387.54 | 374.20K |
| Sep 23 | $379.27 | $382.85 | $374.77 | $378.88 | 177.20K |
| Sep 22 | $377.53 | $383.25 | $374.01 | $379.57 | 374.70K |
| Sep 21 | $381.58 | $381.58 | $373.47 | $377.33 | 311.50K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →